Please login to the form below
melanoma
This page shows the latest melanoma news and features for those working in and with pharma, biotech and healthcare.
BMS claims rapid FDA nod for Opdivo plus Yervoy in kidney cancer
drug. Opdivo and Yervoy have already shown their worth in melanoma, with BMS claiming approval for the combination in that form of skin cancer in 2015, and is also being tested
Latest news
-
Merck’s Keytruda scores in frontline lung cancer yet again
Drug improved overall survival as a monotherapy, which rival BMS’ Opdivo was unable to show
-
Incyte/Merck trial failure bodes ill for IDO class
The pairing of Incyte’s IDO1 inhibitor epacadostat and Merck’s well-established PD1 inhibitor Keytruda (pembrolizumab) had shown promise in mid-stage trials as a treatment for the advanced melanoma, ... We are disappointed that this study did not
-
Sanofi’s PD-1 inhibitor starts EU review for skin cancer
Sanofi has filed cemiplimab in the first instance as a treatment for advanced cutaneous squamous cell carcinoma (CSCC), which it says is the “deadliest form of non-melanoma skin cancer”.
-
NICE says OK to Keytruda for bladder cancer via the CDF
patients in addition to those with non-small-cell lung cancer and melanoma.”. ... Meanwhile, the pharma giant could also see Keytruda close the gap with biggest-selling PD-1 inhibitor Opdivo for melanoma, but that remains to be seen.
-
BMS gets OK for monthly Opdivo dosing
The new monthly injection can be used in a range of cancers, including certain patients with melanoma, non-small cell lung cancer (NSCLC), head and neck, liver, bladder and kidney cancer
More from news
Approximately 75 fully matching, plus 267 partially matching documents found.
Latest Intelligence
-
Lighting the way
The independent review's final report emerged in October 2016, with potential implications for treatment access for a number of conditions, with myeloma, melanoma and dementia highlighted in the publication.
-
Managed Access Programmes: a powerful source of real-world insight
Berking C, Bender A, Schneider L, Erik A, Garbe C, Weichenithal M, Schadendorf D, Hauschild A, Mohr POutcome on 560 metastatic melanoma(MM) patients treated with pembrolizumab during the German expanded
-
Managed Access Programmes: a powerful source of real-world insight
Berking C, Bender A, Schneider L, Erik A, Garbe C, Weichenithal M, Schadendorf D, Hauschild A, Mohr POutcome on 560 metastatic melanoma(MM) patients treated with pembrolizumab during the German expanded
-
Deal Watch February 2016
The lead siDNA, DT01, has been tested in a phase I/II study in metastatic melanoma and Onxeo plans to investigate the potential of this approach in various solid tumours.
-
Pharma deals during July 2014
In this collaboration the focus is Opdivo (nivolumab), an anti-PD-1 antibody that is approved in Japan for unresectable melanoma, and Yervoy (ipilimumab), an anti-CTLA-4 antibody that is ... FDA approved for late-stage melanoma.
More from intelligence
Approximately 0 fully matching, plus 11 partially matching documents found.
Latest appointments
-
Packer Forbes appoints Jade McCudden
McCudden has worked across a number of disease areas including hepatitis C, anticoagulation, Alzheimer's disease, women's health, melanoma and nicotine replacement therapy.
-
Array appoints Victor Sandor chief medical officer
This includes the Colorado, US-based company's binimetinic, a MEK inhibitor in phase III trials for ovarian cancer and melanoma, and filanesib, a KSP inhibitor for multiple myeloma.
-
Bruno Strigini leaves Merck & Co for Novartis
Leading the field though is Strigini's former company Merck &Co, which has already filed MK-3475 in the US to treat advanced melanoma.
-
Chris Bowden joins Agios
During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.
-
Jonathan Dickinson joins Ariad from BMS
The drug made $786m worldwide during 2012 following approvals to treat adult patients with metastatic melanoma who have received prior therapy.
More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.
Latest from PMHub
-
ASCO 2015: What you missed in Chicago
Specifically, we thought the checkpoint inhibitors in head and neck, lung cancer and melanoma really shone. ... Patel SP et al Mol Cancer Ther 2015[2] Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
-
Immuno-oncology; bringing patients closer to treatment
Multi-stakeholder immuno-oncology experience. Blue Latitude Health has worked across a number of immunotherapies in melanoma, lung cancer, myeloma and acute lymphoblastic leukaemia.
-
Immunotherapies in oncology: the future of cancer treatment lies in combinations and partnerships
Yervoy (ipilimumab, Bristol-Myers Squibb) is a first-generation agent which was approved by the FDA in 2011 for advanced melanoma.
-
A stumble, but not a fall – what’s next for Opdivo?
The immuno-oncology treatment won an accelerated FDA approval for metastatic melanoma in December 2014, and has since proved to be a thriving sensation.
-
Why patient education is important in oncology
Why patient education is important in oncology. We talked to Dr Bettina Ryll of Melanoma Patient Network Europe about changes in melanoma treatment and how the added complexity of new treatments ... Therefore, the Melanoma Patient Network Europe has a
More from PMHub
Approximately 1 fully matching, plus 9 partially matching documents found.
Featured jobs
-
Senior Medical Writer
-
Great salary and benefits
-
Senior Programme Executive
-
Salary TBC
-
Scientific Director
-
Great salary and bebefits
- Senior Account Manager / Account Director
-
Great salary and bebefits
- Project Manager, Medical Communications, London
-
Excellent Salary
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
- Account Manager – Med Comms – London
-
Salary TBC
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
- Medical Writer, e-learning/ training, London
-
Excellent Salary
- Project Manager, Medical Communications, Oxford
-
Excellent Salary
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
-
Senior Medical Writer
-
Great salary and bebefits
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
- Group Account Director, Healthcare Brand Communications, London
-
Excellent Package
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
- Editor – Medical Education Agency – Bucks
-
Salary TBC
Subscribe to our email news alerts
No results were found
- P&G agrees $4.2bn buy of Merck KGaA’s consumer health unit
- Publicis LifeBrands Team win UK young Cannes Lions competition
- Sobi poaches Pfizer’s Fredrick Wetterlundh
- Rigel and Ultragenyx claim approvals for rare drugs
- VCCP Health strengthens client service team
- Is agile working benefiting the employee or the organisation?
PMHub
CAN advertising
Brief us and you’ll soon see we really CAN do it all. We’re different to other agencies. You’ll get expert...
Latest intelligence
- The threat of antimicrobial resistance
- Why this issue is such a fundamental challenge...
- Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
- Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
- Unique forum will unite NHS and industry to drive innovation
- HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...
Quick links
Infographics
